Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma

Journal of Immunotherapy

Volumn 27, Issue 3, 2004, Pages 227-231

  Armstrong, Anne C ^a   Dermime, Said ^a   Mulryan, Kate ^a   Stern, Peter L ^a   Bhattacharyya, Tapan ^a   Hawkins, Robert E ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Adoptive; Idiotype; Lymphoma; T cell

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; CHROMIUM 51; CYTOKINE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

EID: 3042530777     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200405000-00007     Document Type: Article

References (20)

1. Papadopoulos EB, Ladamyi M, Emmanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994; 330:1185-1191.
2. Harig S, Witzens M, Krackhardt AM, et al. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood. 2001;98:2999-3005.
3. Syrengelas AD, Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol. 1999; 162:4790-4795.
4. Lauritzsen GF, Weiss S, Bogen B. Anti-tumour activity of idiotype specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand J Immunol. 1993;33:647-656.
5. Kwak LW, Young HA, Pennington RW, et al. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA. 1996;93:10972-10977.
6. Biragyn A, Tani K, Grimm MC, et al. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol. 1999;17:253-258.
7. Haimovich J, Kukulansky T, Weissman B, et al. Rejection of tumors of the B cell lineage by idiotype-vaccinated mice. Cancer Immunol Immunother. 1999;47:330-336.
8. Selmayr M, Menzel H, Kremer JP, et al. B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunity. Cancer Gene Ther. 2000;7:501-506.
9. Armstrong AC, Dermime S, Allinson CG, et al. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype- specific T cell epitope. J Immunol. 2002;168:3983-3991.
10. Kim KJ, Kanellopoulos Langevin C, Merwin RM, et al. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol. 1979;122:549-554.
11. Xu S, Anisumi K, Caceras-Dittmar G. Successive generation of antigen-presenting, dendritic cell lines from murine epidermis. J Immunol. 1995; 154:2697-2705.
12. Shen Z, Reznikoff G, Dranoff G, et al. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol. 1997;158:2723-2730.
13. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152:163-175.
14. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990;60:397-403.
15. Bristol JA, Schlom J, Abrams SI. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer. Cell Immunol. 1999;194:78-89.
16. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
17. Hawkins RE, Russell SJ, Marcus R, et al. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027. Hum Gene Ther. 1997;8:1287-1299.
18. Timmerman JM, Czerwinski DK, Daris TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99:1517-1526.
19. Lundin KU, Hofgaard PO, Omholt H, et al. Therapeutic effect of idiotype-specific CD4 + T cells against B-cell lymphoma in the absence of antiidiotypic antibodies. Blood. 2003;102:605-612.
20. Grillo-Lopez AJ, Hedrick E, Rashford M, et al. Rituximab: ongoing and future clinical development. Semin Oncol. 2002;29:105-112.